Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.53 |
| ▸ | CNR1 | P21554 | 4/20 | 0.53 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30216747 | 0.81 | CNR2 (0.64) | CNR2CNR1 | |
| SCHEMBL27778901 | 0.79 | CNR2 (0.50) | CNR2CNR1CDC25A | |
| SCHEMBL27977990 | 0.77 | CNR2 (0.54) | CNR2CNR1CDC25A | |
| SCHEMBL10526153 | 0.75 | ICMT (0.51) | CNR2CNR1CDC25A | |
| SCHEMBL7712112 | 0.75 | CNR2 (0.59) | CNR2CNR1CDC25A | |
| SCHEMBL17788575 | 0.74 | CNR2 (0.50) | CNR2CNR1CDC25A | |
| SCHEMBL14947367 | 0.74 | CDC25A (0.59) | CNR2CNR1CDC25A | |
| SCHEMBL8363931 | 0.74 | CDC25A (0.59) | CNR2CNR1CDC25A | |
| SCHEMBL27977988 | 0.73 | CNR2 (0.56) | CNR2CNR1CDC25A | |
| SCHEMBL15625751 | 0.73 | CA12 (0.53) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558135-A1 | CONTINUOUS DELIVERY SYSTEMS COMPRISING A CANNABINOID AND MEDICINAL USES THEREOF | Pike Therapeutics Inc. (CA) | 2025-05-28 | — | — | EP | disclosed |
| EP-4326252-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CHRONIC PAIN | Pike Therapeutics, Inc. (CA) | 2024-02-28 | — | — | EP | disclosed |
| EP-4322931-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | Pike Therapeutics Inc. (CA) | 2024-02-21 | — | — | EP | disclosed |
| WO-2024018420-A1 | CONTINUOUS DELIVERY SYSTEMS COMPRISING A CANNABINOID AND MEDICINAL USES THEREOF | Pike Therapeutics Inc. (CA) | 2024-01-25 | — | — | WO | disclosed |
| EP-4196113-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | Pike Therapeutics, Inc. (CA) | 2023-06-21 | — | — | EP | disclosed |
| EP-4175629-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | Pike Therapeutics, Inc. (CA) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023012691-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | PIKE THERAPEUTICS, INC. (CA) | 2023-02-09 | — | — | WO | disclosed |
| EP-4110325-A1 | TRANSDERMAL AND/OR TOPICAL PHARMACEUTICAL FORMULATIONS COMPRISING CANNABIDIOL AND/OR TETRAHYDROCANNABINOL FOR THE TREATMENT OF CHRONIC PAIN | Pike Therapeutics, Inc. (CA) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022224184-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CHRONIC PAIN | PIKE THERAPEUTICS, INC. (CA) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022219468-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | PIKE THERAPEUTICS, INC. 1219014 B.C. LTD. (CA) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022038475-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | PIKE THERAPEUTICS, INC. (CA) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022003623-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | PIKE THERAPEUTICS, INC. (CA) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021214545-A1 | TRANSDERMAL AND/OR TOPICAL PHARMACEUTICAL FORMULATIONS COMPRISING CANNABIDIOL AND/OR TETRAHYDROCANNABINOL FOR THE TREATMENT OF CHRONIC PAIN | PIKE THERAPEUTICS, INC. (CA) | 2021-10-28 | — | — | WO | disclosed |